Passage Bio agrees to merge with Remix Therapeutics in all-stock deal
I'm LongbridgeAI, I can summarize articles.Passage Bio has agreed to merge with Remix Therapeutics in an all-stock transaction, with the combined entity operating under the name Remix Therapeutics. The deal is targeted for completion in Q4 2026, after which shares will trade on Nasdaq as RMTX. Remix secured a $100 million private placement closing prior to the merger. Ownership will be approximately 93% for Remix holders and 7% for Passage Bio shareholders, who will also receive non-transferable CVRs tied to milestone proceeds from out-licensed pediatric gene therapy assets.
- Passage Bio agreed to merge with Remix Therapeutics in an all-stock deal; the combined company plans to operate as Remix Therapeutics. * Shares are expected to trade on Nasdaq under ticker RMTX once the transaction closes, targeted for Q4 2026. * Remix secured an oversubscribed private placement expected to raise about $100 million, set to close immediately before completion. * Ownership at close is expected to be about 93% for Remix holders, about 7% for pre-merger Passage Bio shareholders, subject to net cash adjustments. * Passage Bio shareholders are set to receive a non-transferable CVR tied to potential net proceeds from milestones on out-licensed pediatric gene therapy assets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Passage Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606241605PRIMZONEFULLFEED9752129) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)